Pasar al contenido principal

TERAPIAS INNOVADORAS PARA EL TRATAMIENTO DEL FALLO DE MEDULA EN PACIENTES DE DISQUERATOSIS CONGENITA

PID2021-125077OB-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO DE INVESTIGACION ENERGETICA MEDIOAMBIENTAL Y TECNOLOGICA (CIEMAT)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation

  • Ramos-Hernández, Iris
  • Fuster-García, Carla
  • Aguilar-González, Araceli
  • Lozano-Vinagre, María L.
  • Guenechea-Amurrio, Guillermo
  • Sánchez-Luque, Francisco J.
  • Gonçalves, Manuel A. F. V.
  • Cathomen, Toni
  • Muñoz, P.
  • Molina-Estévez, Francisco J.
  • Martín, Francisco
To improve ex vivo gene therapy strategies involving hematopoietic stem and progenitor cells (HSPCs), we propose a novel knock-in strategy (named KI-Ep) aiming to achieve transgene regulation of the inserted cassette through the acquisition of naturally occurring epigenetic marks. Based on this hypothesis, we selected CX3CR1 (a myeloid-specific gene presenting a poised histone signature on primitive HSPCs) as safe harbor to generate KI-Ep HSPCs. We demonstrated that, unlike the expression pattern achieved with lentiviral vectors (LVs), the insertion of a constitutive expression cassette into the intron 1 of the CX3CR1 locus (CX3CR1-I) in HSPCs resulted in very low expression levels in the more primitive HSPCs but, crucially, strong expression in HSPC-differentiated populations (especially myeloid cells), both in vitro and in vivo. Furthermore, we showed that the promoter of the expression cassette inserted into CX3CR1-I acquired epigenetic marks associated with poised genes during the HSPC stage. These marks transitioned to activated histone states upon KI-Ep HSPCs differentiation. In summary, here, we introduce the KI-Ep concept which enables the epigenetic modulation of the inserted transgene during the HSPCs stem cell stages and its subsequent activation upon differentiation., This work was supported by the by the Fondo Europeo de Desarrollo Regional (FEDER), NextGenerationEU funds—actions of the Recovery and Resilience Mechanism and the Instituto de Salud Carlos III (ISCIII) through the financing research projects [PI18/00337 and PI21/00298 to F.M., and PI21/00875 to P.M.], networks (RICORS-TerAv [RD21/ 0017/0004 to F.M., P.M. and F-J.M-E.; RD21/0017/0027 to G.G-A.] and personal (FI19/00163 to I.R-H.). By the Consejería de Salud y Familias (Junta de Andalucía), under the 2019 call for “Proyectos Estratégicos I + D + I con incorporación de capital humano” [PEER-0286-2019 to P.M.] and FEDER/European Cohesion Fund (FSE) for Andalucía [PECART-0031-2020 to F.M.]; by the Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Junta de Andalucía) through the EMERGIA EMERGIA2020 programe [EMERGIA20_00049 to P.M.]. By the Pompe Competitive Research Grant Program by SPARK Therapeutics [SPARK-2022-002 to F-J.M-E.]; by the Ministerio de Ciencia, Innovación y Universidades [PID2021-125077OB-C22 to G.G-A]; the Ministerio de Ciencia e innovación (MICIN)—líneas estratégicas [PLEC2021-008094 to F.M.] by Ministerio de Ciencia e innovación (MICIN), Plan de Recuperación, transformación y resilencia, Centro para el Desarrollo Tecnológico Industrial (CDTI) and European Union-Next Generation EU [00123009/SNEO-20191072 and PMPTA22/00060 to F.M.]; by the Spanish National Research Agency [AEI; grants RYC2021-031920-I and CNS2022-136033 to F-J.S-L.]. And by the European Union, Horizon Europe Framework Program through the EIC PathfinderChallenges [X-PAND 101070950 to T.C] and the European Cooperation in Science and Technology (COST) [GeneHumdi-CA21113]. Funding to pay the Open Access publication charges for this article was provided by Instituto de Salud Carlos III (ISCIII) [RD21/ 0017/0004]; Universidad de Granada/CBUA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Premature ageing of lung alveoli and bone marrow cells from Terc deficient mice with different telomere lengths

  • Guerrero-López, Rosa
  • Manguan-García, Cristina
  • Carrascoso-Rubio, C.
  • Lozano, M. L.
  • Toldos-Torres, Marta
  • García-Castro, Laura
  • Sánchez-Dominguez, Rebeca
  • Alberquilla, Omaira
  • Sánchez-Pérez, Isabel
  • Molina-Molina, María
  • Bueren-Calabuig, Juan A.
  • Guenechea, Guillermo
  • Perona Abellón, Rosario
  • Sastre, Leandro
Telomeres are terminal protective chromosome structures. Genetic variants in genes coding for proteins required for telomere maintenance cause rare, life-threatening Telomere Biology Disorders (TBDs) such as dyskeratosis congenita, aplastic anemia or pulmonary fibrosis. The more frequently used mice strains have telomeres much longer than the human ones which question their use as in vivo models for TBDs. One mice model with shorter telomeres based on the CAST/EiJ mouse strain carrying a mutation in the Terc gene, coding for the telomerase RNA component, has been studied in comparison with C57BL/6J mice, carrying the same mutation and long telomeres. The possible alterations produced in lungs and the haematopoietic system, frequently affected in TBD patients, were determined at different ages of the mice. Homozygous mutant mice presented a very shortened life span, more notorious in the short-telomeres CAST/EiJ strain. The lungs of mutant mice presented a transitory increase in fibrosis and a significant decrease in the relative amount of the alveolar epithelial type 2 cells from six months of age. This decrease was larger in mutant homozygous animals but was also observed in heterozygous animals. On the contrary the expression of the senescence-related protein P21 increased from six months of age in mutant mice of both strains. The analysis of the haematopoietic system indicated a decrease in the number of megakaryocyte-erythroid progenitors in homozygous mutants and an increase in the clonogenic potential of bone marrow and LSK cells. Bone marrow cells from homozygous mutant animals presented decreasing in vitro expansion capacity. The alterations observed are compatible with precocious ageing of lung alveolar cells and the bone marrow cells that correlate with the alterations observed in TBD patients. The alterations seem to be more related to the genotype of the animals that to the basal telomere length of the strains although they are more pronounced in the short-telomere CAST/EiJ-derived strain than in C57BL/6J animals. Therefore, both animal models, at ages over 6–8 months, could represent valuable and convenient models for the study of TBDs and for the assay of new therapeutic products., The project was supported by grants PI20-00335 and PI23-00677 from the Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain, co-funded by European Regional Development (FEDER) funds and Ministerio de Ciencia, Innovación y Universidades PID2021-125077OB-C22., Peer reviewed